Insmed Incorporated (INSM)

Market Cap	13.29B
Revenue (ttm)	363.71M
Net Income (ttm)	-913.77M
Shares Out	181.00M
EPS (ttm)	-5.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,360,477
Open	71.71
Previous Close	72.00
Day's Range	70.30 - 73.45
52-Week Range	21.92 - 84.91
Beta	1.28
Analysts	Strong Buy
Price Target	95.36 (+29.85%)
Earnings Date	May 8, 2025

About INSM

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2000
• Employees: 1,271
• Stock Exchange: NASDAQ
• Ticker Symbol: INSM
• Website: https://www.insmed.com

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Analyst Forecast

According to 16 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $95.36, which is an increase of 29.85% from the latest price.

Price Target

$95.36

(29.85% upside)

Analyst Consensus: Strong Buy